---
title: "Boston Scientific rose over 4.4%, Q3 performance exceeded expectations + raised full-year adjusted earnings guidance"
description: "Boston Scientific's stock price rose more than 4.4%, reaching $104.36. Third-quarter sales increased by 20% year-on-year to $5.07 billion, exceeding analyst expectations. Sales in the cardiovascular s"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262272160.md"
published_at: "2025-10-22T14:50:21.000Z"
---

# Boston Scientific rose over 4.4%, Q3 performance exceeded expectations + raised full-year adjusted earnings guidance

> Boston Scientific's stock price rose more than 4.4%, reaching $104.36. Third-quarter sales increased by 20% year-on-year to $5.07 billion, exceeding analyst expectations. Sales in the cardiovascular segment grew by 22% to $3.34 billion, with adjusted earnings per share of $0.75, higher than expected. The company raised its full-year adjusted earnings per share guidance to $3.02 to $3.04, surpassing the analyst expectation of $2.98

Medical device company Boston Scientific rose over 4.4%, closing at $104.36. On the news front, Boston Scientific's third-quarter sales increased by 20% year-on-year to $5.07 billion, exceeding Wall Street analysts' expectations of $4.97 billion. Among them, the cardiovascular division's sales grew by 22% year-on-year to $3.34 billion, higher than the expected $3.27 billion. During the period, the adjusted earnings per share were $0.75, above the expected $0.71. The company raised its full-year adjusted earnings per share guidance to $3.02 to $3.04, surpassing analysts' expectations of $2.98

### Related Stocks

- [BSX.US - Boston Scientific](https://longbridge.com/en/quote/BSX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Boston Scientific’s TheraSphere Trial in Japan Signals New Growth Path in Liver Cancer | Boston Scientific (BSX) is conducting the TheraSphere Japan Pre-Market Study to evaluate a liver cancer treatment for pa | [Link](https://longbridge.com/en/news/276465329.md) |
| Assetmark Inc. Sells 82,501 Shares of Boston Scientific Corporation $BSX | Assetmark Inc. has reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 41.6%, selling 82,501 shares in the  | [Link](https://longbridge.com/en/news/276044910.md) |
| If You Invested $100 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today | Boston Scientific (NYSE:BSX) has delivered an average annual return of 18.55% over the past 15 years, outperforming the  | [Link](https://longbridge.com/en/news/271667047.md) |
| Boston Scientific Corporation $BSX Shares Purchased by Gladstone Institutional Advisory LLC | Gladstone Institutional Advisory LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 39.5% in Q3, own | [Link](https://longbridge.com/en/news/271652191.md) |
| Boston Scientific: Undervalued Ahead of Strong Q4 Results, 2026 Outlook, and PEN Acquisition Catalyst | TD Cowen analyst Josh Jennings maintains a Buy rating on Boston Scientific (BSX), citing unjustified recent share weakne | [Link](https://longbridge.com/en/news/272882910.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.